Moreover, two cases were followed up to 16 months during radiotherapy or chemotherapy or targeted therapy: their serum and exosomal BATF2 mRNA expressions were upregulated following clinical treatments but decreased at the diagnosis of recurrent NPC (Figures 4G,H). Here, BATF2 is linked to nasopharyngeal carcinoma.